Apr 10 2025
CRYSTAL-1 Study: A Study of ORX750 in Participants with Narcolepsy and Idiopathic Hypersomnia

NOW RECRUITING adults (ages 18-65) with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in the U.S. and Canada. Orexin is a chemical in the brain that helps people to stay awake during the daytime. The purpose of this clinical trial is to evaluate the safety and efficacy of ORX750, an oral investigational orexin agonist, in people with NT1, NT2, and IH.

For further information about this clinical study, please see details at ClinicalTrials.gov. You will be able to review the study information, participation criteria, current locations, and study plan. If you have further interest in this study as a potential participant, please contact the study sponsor at CRYSTAL-1@centessa.com. Compensation for time and travel may be available.